PAMAM dendrimers functionalised with an anti-TNF α antibody and chondroitin sulphate for treatment of rheumatoid arthritis

Rheumatoid arthritis is a chronic autoimmune disease characterised by joint synovial inflammation, along with cartilage and bone tissue destruction. Dendrimers can offer new opportunities as drug delivery systems of molecules interest. Herein we aimed to develop poly(amidoamine) dendrimers (PAMAM), functionalised chondroitin sulphate (CS), lined anti-TNF α antibodies (Abs) provide anti-inflammatory properties. Physicochemical characterisation demonstrated that anti-TNFα Abs-CS/PAMAM dendrimer NPs were successfully produced. The in vitro studies revealed CS/PAMAM did not affect the ATDC5 THP-1 cell lines' metabolic activity proliferation, presenting good cytocompatibility hemocompatibility. Moreover, showed suitable TNF capture capacity, making them appealing for immunotherapies RA patients.